More about

Hypertriglyceridemia

News
June 03, 2024
3 min read
Save

Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.

News
May 29, 2024
5 min read
Save

RNA interference agents appear to benefit patients with mixed hyperlipidemia

In two phase 2b trials, RNA interference agents were associated with reductions in triglycerides compared with placebo for patients with mixed hyperlipidemia.

News
May 20, 2024
2 min read
Save

To test or not to test: Isotretinoin marginally increases risk for severe adverse events

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

News
April 09, 2024
2 min read
Save

Plozasiran lowers triglycerides for 48 weeks in patients with severe hypertriglyceridemia

ATLANTA — Plozasiran provided sustained reduction in triglycerides, apolipoprotein C-III and remnant cholesterol out to 48 weeks for patients with severe hypertriglyceridemia, a speaker reported.

News
April 07, 2024
3 min read
Save

Monthly olezarsen reduced triglyceride levels by 50%

ATLANTA — Monthly administration of subcutaneous olezarsen substantially reduced triglyceride levels compared with placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk, according to new phase 2 data.

Learn the Heart

Part of the Healio Network

Icosapent Ethyl Topic Review

Icosapent ethyl is a prescription-grade derivative of the omega-3 fatty acid eicosapentaenoic acid, a component of fish oil.

News
November 13, 2023
2 min read
Save

Top in cardiology: New options for statin intolerance; heart benefits of Wegovy

There are many new treatment strategies for patients with statin intolerance. Finding a regimen that is acceptable to the patient may require switching agents, changing dosages or using alternative regimens, according to experts.

News
November 05, 2023
2 min read
Save

News you may have missed from the 2023 Cardiometabolic Health Congress

Healio and Cardiology Today have aggregated news you may have missed from the 2023 Cardiometabolic Health Congress in Boston.

News
October 30, 2023
1 min read
Save

Top in cardiology: New agents to lower triglycerides; FDA OKs extravascular ICD system

After years of failed attempts to develop therapies meant to reduce elevated triglycerides, novel agents are now showing promise in the management of hypertriglyceridemia, a speaker said.

News
October 23, 2023
3 min read
Save

After many failed trials, novel therapeutics may finally tackle high triglycerides

BOSTON — After years of failed clinical trials with agents to lower severely elevated triglycerides, emerging therapeutics hold promise for effectively addressing hypertriglyceridemia and reducing associated CV risks, a speaker reported.

View more